Therefore, this follow-up study provides additional evidence supporting the therapeutic potential of G-CSF to attenuate HT and other detrimental effects of delayed tPA therapy and, thus, to extend the limited therapeutic time window of tPA treatment for ischemic stroke. This evidence concerns the gene PLAT and ischemic stroke.